ACTUALEYES INC.
Last updated: March 15, 2021 ActualEyes has developed therapeutics and products for treating Fuchs' corneal endothelium dystrophy. The products developed are eyedrops, regenerative cell-therapy based products, and therapeutics such as AE001 (phase I) and AE002.
ACTUALEYES INC.
Industry:
Biotechnology Health Care Hospital
Founded:
2018-05-01
Address:
Kyoto, Kyoto, Japan
Country:
Japan
Website Url:
http://www.actualeyes.co.jp
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt WordPress Apache Wordpress Plugins Mobile Non Scaleable Content
Current Employees Featured
Official Site Inspections
http://www.actualeyes.co.jp
- Host name: www1006.onamae.ne.jp
- IP address: 160.251.148.20
- Location: Tokyo Japan
- Latitude: 35.6882
- Longitude: 139.7532
- Timezone: Asia/Tokyo
- Postal: 102-0082
More informations about "ActualEyes Inc."
Company | ActualEyes, Inc.
May 1, 2018 ActualEyes Inc. Room 314, D-egg, 1 Koudojizoya, Kyotanabe-shi, Kyoto 610-0332, Japan. CONTACT US. CONTACT FORM. LINKS. Koizumi Research Laboratory, Department …See details»
ActualEyes - Crunchbase Company Profile & Funding
Organization. ActualEyes . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone Number +81 077 …See details»
Vision | ActualEyes, Inc.
ActualEyes, Inc. was formed to develop the therapeutic drugs for corneal endothelial regenerative medicine and Fuchs corneal endothelial dystrophy discovered at Doshisha University. The corporation’s goal is to ensure the …See details»
Contact Us | ActualEyes, Inc.
ActualEyes Inc. Room 314, D-egg, 1 Koudojizoya, Kyotanabe-shi, Kyoto 610-0332, Japan. CONTACT US. CONTACT FORM. LINKS. Koizumi Research Laboratory, Department of ...See details»
ActualEyes Company Profile 2024: Valuation, Funding & Investors
ActualEyes General Information Description. Developer of regenerative drugs and eye drops designed to treat Fuchs corneal endothelial dystrophy. The company's drugs combine cultured …See details»
ActualEyes, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore ActualEyes, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Disease Domain:Infectious Diseases, Nervous System Diseases ...See details»
ACTUALEYES INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for ACTUALEYES INC. of KYOTANABE, KYOTO. Get the latest business insights from Dun & Bradstreet. D&B …See details»
ActualEyes - Overview, News & Similar companies | ZoomInfo.com
View ActualEyes (www.actualeyes.co.jp) location in Japan , revenue, industry and description. Find related and similar companies as well as employees by title and much more. ...See details»
ActualEyes - Products, Competitors, Financials, Employees, …
ActualEyes is a clinical-stage biotech company dedicated to research and development of stem cell transplantation for corneal endothelial diseases. In September 2021, RegeneRx …See details»
ActualEyes - Contacts, Employees, Board Members, Advisors
ActualEyes is a healthcare center that replaces corneal transplantation with innovative cell therapy and pharmaceutical treatment. Search Crunchbase. Start Free Trial . Chrome …See details»
Santen and ActualEyes sign a joint development ... - Santen …
Nov 18, 2021 ActualEyes is committed to research and development of both pharmacological treatments for FECD and the cell therapy for corneal endothelial dysfunction. For more …See details»
Arctic Vision announces exclusive licensing agreement with …
May 14, 2021 For more information, please visit www.actualeyes.co.jp. About Arctic Vision Arctic Vision is a China -based clinical stage specialty ophthalmology company with a leading …See details»
ActualEyes: Employee Directory | ZoomInfo.com
ActualEyes corporate office is located in Japan and has 2 employees. actualeyes inc. actualeyes. ActualEyes Global Presence. Location: People at location: North America: 2: Asia: 1: Search …See details»
News | ActualEyes, Inc.
Mar 27, 2024 ActualEyes Inc. announces the implementation of Series C financing by a domestic pharmaceutical company, bringing its accumulated fundraising to 850 million JPY. …See details»
Arctic Vision announces exclusive licensing agreement with …
[email protected]. Reference: [i] Kinoshita, Shigeru & Koizumi, Noriko et al. (2018). Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy. The New …See details»
Arctic Vision in exclusive licensing pact with ActualEyes
May 14, 2021 Arctic Vision of Shanghai and Japanese-based ActualEyes announced an exclusive licensing agreement for Arctic Vision to develop and commercialize ActualEyes’ lead …See details»
News | ActualEyes, Inc.
Jun 13, 2024 ActualEyes Inc. is pleased to announce the submission of the Phase II clinical trial protocol for “AE101,” a cutting-edge therapy for the treatment of bullous keratopathy, to the …See details»
Doshisha Offshoot Eyes Nationwide Delivery of Cryopreserved Cell ...
Oct 17, 2024 The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti …See details»
Technology | ActualEyes, Inc.
In November 2021, ActualEyes, Inc. entered into a Phase II clinical trial (Phase IIa / POC) with Santen Pharmaceutical Co., Ltd. for a sirolimus ophthalmic solution (Santen development …See details»
News | ActualEyes, Inc.
Santen and ActualEyes sign a joint development agreement on Phase II clinical trial (Phase II a / PoC study) for a treatment candidate for Fuchs endothelial corneal dystrophy. PDF. …See details»